Google and drug giant GlaxoSmithKline are spending £540m on a new joint venture, Galvani Bioelectronics, in a bid to develop and commercialise bioelectronic medicine.
The partnership between Verily Life Sciences, previously known as Google Life Sciences, and GSK, will boost the British pharmaceutical giant’s efforts in bioelectronic medicine which it has been dabbling in since 2012.
Galvani Bioelectronics will be headquartered in Stevenage, within GSK’s R&D centre, and another branch will be located at Verily’s facilities in south San Francisco.
Bioelectronic medicine is a relatively new scientific field that uses tiny, implantable devices to monitor and control electrical signals within the body.The nervous system contains billions of neurons – cells that operate on electrical pulses in order to perform a specific function. GSK believes that certain chronic conditions such as arthritis, diabetes and asthma could potentially be treated using bioelectronic medicine.
A bioelectronic device works by targeting a specific area. The goal is to record neural electrical activity, analyse this data in real time, so that the neural signal can be regulated for therapeutic benefits.
Read more here..
Source: The Register